Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30628
Title: | A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement | Authors: | Dangas, George D. Tijssen, Jan G. P. Woehrle, Jochen Sondergaard, Lars Gilard, Martine Moellmann, Helge Makkar, Raj R. Herrmann, Howard C. Giustino, Gennaro Baldus, Stephan De Backer, Ole Guimaraes, Ana H. C. Gullestad, Lars Kini, Annapoorna von Lewinski, Dirk Mack, Michael Moreno, Raul Schaefer, Ulrich Seeger, Julia Tchetche, Didier Thomitzek, Karen Valgimigli, Marco VRANCKX, Pascal Welsh, Robert C. Wildgoose, Peter Volkl, Albert A. Zazula, Ana van Amsterdam, Ronald G. M. Mehran, Roxana Windecker, Stephan |
Issue Date: | 2020 | Publisher: | MASSACHUSETTS MEDICAL SOC | Source: | NEW ENGLAND JOURNAL OF MEDICINE, 382 (2) , p. 120 -129 | Abstract: | Background Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear. Methods We randomly assigned 1644 patients without an established indication for oral anticoagulation after successful TAVR to receive rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months) (rivaroxaban group) or aspirin at a dose of 75 to 100 mg daily (with clopidogrel at a dose of 75 mg daily for the first 3 months) (antiplatelet group). The primary efficacy outcome was the composite of death or thromboembolic events. The primary safety outcome was major, disabling, or life-threatening bleeding. The trial was terminated prematurely by the data and safety monitoring board because of safety concerns. Results After a median of 17 months, death or a first thromboembolic event (intention-to-treat analysis) had occurred in 105 patients in the rivaroxaban group and in 78 patients in the antiplatelet group (incidence rates, 9.8 and 7.2 per 100 person-years, respectively; hazard ratio with rivaroxaban, 1.35; 95% confidence interval [CI], 1.01 to 1.81; P=0.04). Major, disabling, or life-threatening bleeding (intention-to-treat analysis) had occurred in 46 and 31 patients, respectively (4.3 and 2.8 per 100 person-years; hazard ratio, 1.50; 95% CI, 0.95 to 2.37; P=0.08). A total of 64 deaths occurred in the rivaroxaban group and 38 in the antiplatelet group (5.8 and 3.4 per 100 person-years, respectively; hazard ratio, 1.69; 95% CI, 1.13 to 2.53). Conclusions In patients without an established indication for oral anticoagulation after successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy. (Funded by Bayer and Janssen Pharmaceuticals; GALILEO ClinicalTrials.gov number, NCT02556203.) | Notes: | Windecker, S (reprint author), Univ Bern, Univ Hosp Bern, Inselspital, Freiburgstr 18, CH-3010 Bern, Switzerland. stephan.windecker@insel.ch |
Other: | Windecker, S (reprint author), Windecker, S (reprint author) stephan.windecker@insel.ch | Document URI: | http://hdl.handle.net/1942/30628 | ISSN: | 0028-4793 | e-ISSN: | 1533-4406 | DOI: | 10.1056/NEJMoa1911425 | ISI #: | WOS:000506581500010 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
nejmoa1911425.pdf | Published version | 339.09 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
40
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
349
checked on Oct 6, 2024
Page view(s)
36
checked on Jun 15, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.